Entering text into the input field will update the search result below

Hutchmed, AstraZeneca launch Phase III Orpathys + Tagrisso combo study in China in lung cancer

Human lungs on scientific background.3d illustration

Mohammed Haneefa Nizamudeen/iStock via Getty Images

  • Hutchmed (China) (​HCM) and AstraZeneca (​AZN) have initiated SACHI, a China Phase III study of Orpathys (savolitinib) in combination with AstraZeneca’s Tagrisso (osimertinib) for the treatment of patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
AZN
--
HCM
--